Recombinant human interferon omega (Southwest Pharmaceutical)

重组人干扰素ω（西南药业）

Report date: 2022/04/18 09:47:30

Base Information

Drug NameRecombinant human interferon omega (Southwest Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCoronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesChinese Academy Of Military Medical Sciences
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesAurora Optoelectronics Co LtdInstitute Of Microbiology And Epidemiology, Chinese Academy Of Military Medical Sciences
Active IndicationsN/A
Inactive IndicationsCoronavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A